Type 2 diabetes

Ehtasham Ahmad; Soo Lim; Roberta Lamptey; David R. Webb; Melanie J. Davies

doi:10.1016/S0140-6736(22)01655-5

Type 2 diabetes

Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R. Webb, Melanie J. Davies

Research output: Contribution to journal › Review article › peer-review

328 Scopus citations

Abstract

Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes worldwide. The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). Early detection and proactive management are crucial for prevention and mitigation of microvascular and macrovascular complications and mortality burden. Access to novel therapies improves person-centred outcomes beyond glycaemic control. Precision medicine, including multiomics and pharmacogenomics, hold promise to enhance understanding of disease heterogeneity, leading to targeted therapies. Technology might improve outcomes, but its potential is yet to be realised. Despite advances, substantial barriers to changing the course of the epidemic remain. This Seminar offers a clinically focused review of the recent developments in type 2 diabetes care including controversies and future directions.

Original language	English
Pages (from-to)	1803-1820
Number of pages	18
Journal	The Lancet
Volume	400
Issue number	10365
DOIs	https://doi.org/10.1016/S0140-6736(22)01655-5
State	Published - 19 Nov 2022

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(22)01655-5

Cite this

@article{a13110ec45a64318ab66257bd99e4544,

title = "Type 2 diabetes",

abstract = "Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes worldwide. The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). Early detection and proactive management are crucial for prevention and mitigation of microvascular and macrovascular complications and mortality burden. Access to novel therapies improves person-centred outcomes beyond glycaemic control. Precision medicine, including multiomics and pharmacogenomics, hold promise to enhance understanding of disease heterogeneity, leading to targeted therapies. Technology might improve outcomes, but its potential is yet to be realised. Despite advances, substantial barriers to changing the course of the epidemic remain. This Seminar offers a clinically focused review of the recent developments in type 2 diabetes care including controversies and future directions.",

author = "Ehtasham Ahmad and Soo Lim and Roberta Lamptey and Webb, {David R.} and Davies, {Melanie J.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = nov,

day = "19",

doi = "10.1016/S0140-6736(22)01655-5",

language = "English",

volume = "400",

pages = "1803--1820",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Ltd",

number = "10365",

}

TY - JOUR

T1 - Type 2 diabetes

AU - Ahmad, Ehtasham

AU - Lim, Soo

AU - Lamptey, Roberta

AU - Webb, David R.

AU - Davies, Melanie J.

PY - 2022/11/19

Y1 - 2022/11/19

N2 - Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes worldwide. The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). Early detection and proactive management are crucial for prevention and mitigation of microvascular and macrovascular complications and mortality burden. Access to novel therapies improves person-centred outcomes beyond glycaemic control. Precision medicine, including multiomics and pharmacogenomics, hold promise to enhance understanding of disease heterogeneity, leading to targeted therapies. Technology might improve outcomes, but its potential is yet to be realised. Despite advances, substantial barriers to changing the course of the epidemic remain. This Seminar offers a clinically focused review of the recent developments in type 2 diabetes care including controversies and future directions.

AB - Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes worldwide. The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). Early detection and proactive management are crucial for prevention and mitigation of microvascular and macrovascular complications and mortality burden. Access to novel therapies improves person-centred outcomes beyond glycaemic control. Precision medicine, including multiomics and pharmacogenomics, hold promise to enhance understanding of disease heterogeneity, leading to targeted therapies. Technology might improve outcomes, but its potential is yet to be realised. Despite advances, substantial barriers to changing the course of the epidemic remain. This Seminar offers a clinically focused review of the recent developments in type 2 diabetes care including controversies and future directions.

UR - http://www.scopus.com/inward/record.url?scp=85142001813&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(22)01655-5

DO - 10.1016/S0140-6736(22)01655-5

M3 - Review article

C2 - 36332637

AN - SCOPUS:85142001813

SN - 0140-6736

VL - 400

SP - 1803

EP - 1820

JO - The Lancet

JF - The Lancet

IS - 10365

ER -

Type 2 diabetes

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this